FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ĪĒ

					Washington, D.C. 20549										(OMB	APPRO\	/AL	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
transac contrac the pur securiti to satis	chase or sale or es of the issue fy the affirmation ons of Rule 10b	pursuant to a written plan for of equity r that is intended ve defense																	
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Ticho Barry</u>					<u>St</u>	Stoke Therapeutics, Inc. [STOK]								Director 10% Owner				ner	
					-										Officer (give title Other (specify below)			pecify	
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC.)	3. Date of Earliest Transaction (Month/Day/Year) 10/01/2024									CHIEF MEDICAL OFFICER					
45 WIGGINS AVENUE																			
					_ 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Jo Line)									Joint/Group	Filing	(Check App	licable	
(Street) BEDFOI	(Street) BEDFORD MA 01730					Form Form										filed by One Reporting Person filed by More than One Reporting			
(City) (State) (Zip)						Person													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities / Disposed Of (Acquired (A) or (D) (Instr. 3, 4 and 5)		Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		n: Direct c r Indirect E Instr. 4) 0	7. Nature of Indirect Beneficial Dwnership		
									Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock 10/01/202				2024	24		Μ		10,000	A	\$0.6	\$0.6 12,4		D					
Common Stock 10/01/202				2024	24			S ⁽¹⁾	\square	10,000	D	\$12.064	8 ⁽²⁾ 2	485		D			
		-	Table								posed of,			v Owned					
1. Title of Derivative	2.	3. Transaction Date (Month/Day/Year)	3A. Dee		4.		5. Number		6. Date Exercisable and		cisable and	7. Title and Amo of Securities		8. Price of Derivative	9. Number		10. Ownership	11. Nature of Indirect	
Security (Instr. 3)	Conversion or Exercise Price of Derivative Security		if any	/Day/Year)		Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)			ng ve Security and 4)	Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	s Ily	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$0.6	10/01/2024		М				10,000	(3)		04/02/2028	Commor Stock	10,000	\$0	20,000		D		
	n of Respons																		

1. The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.63 to \$12.42 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

<u>/s/ Jonathan Allan, Attorney-in-</u>	10/02/2024
Fact	10/02/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.